home / stock / incy / incy news


INCY News and Press, Incyte Corporation From 05/05/20

Stock Information

Company Name: Incyte Corporation
Stock Symbol: INCY
Market: NASDAQ
Website: incyte.com

Menu

INCY INCY Quote INCY Short INCY News INCY Articles INCY Message Board
Get INCY Alerts

News, Short Squeeze, Breakout and More Instantly...

INCY - Incyte Corp (INCY) Q1 2020 Earnings Call Transcript

Image source: The Motley Fool. Incyte Corp   (NASDAQ: INCY) Q1 2020 Earnings Call May 5, 2020 , 8:00 a.m. ET Operator Continue reading

INCY - Incyte Corporation (INCY) CEO Hervé Hoppenot on Q1 2020 Results - Earnings Call Transcript

Incyte Corporation (INCY) Q1 2020 Results Earnings Conference Call May 05, 2020, 08:00 AM ET Company Participants Michael Booth - Divisional Vice President of Investor Relations and Corporate Social Responsibility Hervé Hoppenot - Chairman, President, and Chief Executive Offic...

INCY - Incyte Reports a Q1 Loss Due to MorphoSys Deal

Incyte (NASDAQ: INCY) delivered its first-quarter results before the market opened on Tuesday, reporting revenue up 14% year over year to $569 million, which topped the analysts' average estimate of $556 million. But the biotech recorded a GAAP net loss of $720.6 million, or $3.3...

INCY - Incyte Corporation 2020 Q1 - Results - Earnings Call Presentation

The following slide deck was published by Incyte Corporation in conjunction with their 2020 Q1 earnings Read more ...

INCY - Incyte Q1 Jakafi sales up 22%; guidance affirmed

Incyte ( INCY ) Q1 results : More news on: Incyte Corporation, Healthcare stocks news, Earnings news and commentary, , Read more ...

INCY - Incyte EPS misses by $2.50, beats on revenue

Incyte (NASDAQ: INCY ): Q1 Non-GAAP EPS of -$2.86 misses by $2.50 ; GAAP EPS of -$3.33 misses by $2.08 . More news on: Incyte Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...

INCY - Incyte Reports 2020 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Total product and royalty revenues of $569 million (+24% vs Q1   2019) for the quarter ended March 31, 2020; Jakafi ® (ruxolitinib) revenues of $459 million in Q1   2020 (+22% vs Q1   2019) Pemazyre ™ (pemigatinib) approved by FDA as first targeted...

INCY - Morgan Stanley cuts view on Incyte in premarket analyst action

Mersana Therapeutics (NASDAQ: MRSN ) initiated with Buy rating and $14 (50% upside) price target at BTIG Research. Shares up  2%  premarket. More news on: Mersana Therapeutics, Inc., Viela Bio, Inc., Y-mAbs Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Rea...

INCY - Coronavirus Roundtable - The Stock Picker's Market Vs. The Macro

The coronavirus outbreak and the effects of COVID-19 have gone deeper and wider than most people would have expected. That applies just as much to markets as anywhere. Whether it's a tech sector that is supporting our new work from home or re-rating as expensive EV/Sales multiples make less se...

INCY - Stocks To Watch: Tech Powerhouses Lead Earnings Blitz

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Previous 10 Next 10